🎯 Peptide-Drug Conjugate (PDC) Landscape
Peptide-drug conjugates (PDCs) represent the next-generation targeted delivery technology following ADCs (antibody-drug conjugates), enabling precise delivery of cytotoxic drugs via peptide ligands. Compared to ADCs, PDCs offer smaller molecular weight, better tissue penetration, lower immunogenicity, and controllable production costs. This chapter provides a comprehensive analysis of the PDC pipeline, technology comparisons, and industry landscape.
1. PDC Structural Components
| Component |
Function |
Optional Types |
| Targeting Peptide |
Recognizes and binds overexpressed receptors on tumor cells |
RGD peptide (αvβ3 integrin), NGR peptide (CD13), Somatostatin analog (SSTR2), LHRH analog, GLP-1 analog |
| Linker |
Connects peptide and payload, controls drug release |
Cleavable (enzyme-sensitive/acid-sensitive/reduction-sensitive), Non-cleavable |
| Payload |
Cytotoxic drug |
MMAE, MMAF, DOX, Paclitaxel, Camptothecin, PBD dimer |
2. Marketed PDC Drugs — In-Depth Analysis
| Drug Name |
Targeting Peptide |
Payload |
Linker |
Indication |
Approval Year |
Company |
Market Performance |
| Pepaxto (Melflufen) |
Non-targeted (enhanced lipophilicity) |
Melphalan |
Cleavable |
Multiple myeloma |
2021 (FDA, withdrawn 2023) |
Oncopeptides |
Did not meet survival endpoint; accelerated approval withdrawn |
| Lutathera (¹⁷⁷Lu-DOTATATE) |
Somatostatin analog (octreotide) |
¹⁷⁷Lu |
DOTA chelator |
GEP-NETs |
2018 (FDA/EU) |
AAA/Novartis |
2024 sales $0.72B; NET first-line standard of care |
| Pluvicto (¹⁷⁷Lu-PSMA-617) |
PSMA-targeting peptide |
¹⁷⁷Lu |
DOTA chelator |
mCRPC |
2022 (FDA) |
Novartis |
2024 sales $1.58B, +66% growth |
| Somatuline Autogel (Lanreotide) |
Somatostatin analog |
Lanreotide |
— |
Acromegaly / GEP-NETs |
2007 |
Ipsen |
2024 sales €1.26B |
| Signifor (Pasireotide) |
Somatostatin analog |
Pasireotide |
— |
Cushing's disease / Acromegaly |
2012 |
Recordati |
Orphan drug status |
Key Takeaways
The withdrawal of Pepaxto underscores that targeting specificity is critical for PDCs. Conversely, the success of Lutathera and Pluvicto validates the commercial viability of radiopharmaceutical PDCs — radionuclide PDCs have become the most mature PDC segment to date.
3. Clinical-Stage PDC Pipeline Overview
| Candidate |
Targeting Peptide |
Payload |
Indication |
Phase |
Company |
Linker Type |
| TH1902 |
Sortilin-targeting peptide |
DOX |
Triple-negative breast / Ovarian cancer |
Phase I/II |
Theratechnologies |
Cleavable (enzyme-sensitive) |
| CBX-12 |
pHLIP peptide (acidic microenvironment) |
Exatecan |
Solid tumors |
Phase I |
Cybrexa Therapeutics |
pH-sensitive |
| BT1718 |
MT1-MMP-targeting bicycle peptide |
DM1 |
Solid tumors |
Phase I/II |
Bicycle Therapeutics |
Reduction-sensitive (disulfide) |
| BT8009 |
Nectin-4-targeting bicycle peptide |
MMAE |
Urothelial carcinoma |
Phase II/III |
Bicycle Therapeutics |
Cleavable (Val-Cit) |
| BT5528 |
EphA2-targeting bicycle peptide |
MMAE |
Solid tumors |
Phase I/II |
Bicycle Therapeutics |
Cleavable |
| BT7480 |
Nectin-4/CD137 dual-targeting peptide |
— |
Solid tumors |
Phase I |
Bicycle Therapeutics |
Dual-targeting (no payload) |
| BGC0222 |
Cyclic RGD peptide |
CPT (camptothecin) |
Solid tumors |
Phase I |
Biosion Biotech (China) |
Cleavable |
| CEND-1 |
iRGD tumor-penetrating peptide |
Gemcitabine + Nab-Paclitaxel combo |
Pancreatic cancer |
Phase III |
Cend Therapeutics |
Penetrating peptide (non-covalent) |
| PPMX-T001 |
Hypoxia-targeting peptide |
SN-38 |
Solid tumors |
Phase I |
PPMX (Japan) |
Reduction-sensitive |
| RC-130 |
RGD peptide |
MMAE |
Melanoma / Glioma |
Phase I |
Rada/Cue (China) |
Enzyme-sensitive |
| KP-1104 |
LHRH analog |
DM1 |
Ovarian / Breast cancer |
Phase I |
Kura Oncology |
pH-sensitive |
| SarCNU |
Chloroethylating GABA peptide mimetic |
Chloroethylation |
Glioma |
Phase II |
Vivia Biotech |
— |
| PEN-866 |
Heat shock protein-targeting peptide |
SN-38 |
Solid tumors |
Phase I/II |
Endocyte/Novartis |
Enzyme-sensitive |
| ABT-414 |
EGFR-targeting peptide |
MMAF |
Glioblastoma |
Phase III |
AbbVie |
Non-cleavable |
| AM-001 |
Integrin αvβ3-targeting peptide |
Paclitaxel |
Solid tumors |
Phase I |
Apertis Medical |
pH-sensitive |
| EA-230 |
Renal tubule-targeting peptide |
Immunomodulator |
Sepsis AKI |
Phase II |
Erendis Pharma |
— |
| ZP-111 |
GLP-1/GLP-2 dual-targeting |
Peptide payload |
Short bowel syndrome |
Phase II |
Zealand Pharma |
— |
| RL-101 |
Cyclic peptide IBD-targeting |
JAK inhibitor |
IBD |
Phase I |
Ralex Pharma |
Enzyme-sensitive |
| NP-728 |
CendR penetrating peptide |
Cisplatin |
Ovarian cancer |
Phase I/II |
Navigen Pharma |
Cleavable |
4. Linker Technology Comparison
| Linker Type |
Cleavage Conditions |
Plasma Stability |
Tumor Selectivity |
Release Kinetics |
Representative Application |
| Enzyme-Sensitive (Cathepsin B) |
Cathepsin B cleaves Val-Cit |
High |
Medium–High |
Fast (2–6h) |
BT8009 (Val-Cit-PABC-MMAE) |
| pH-Sensitive (Hydrazone) |
Hydrolysis at pH 5.0–6.0 |
Medium |
Medium |
Moderate (12–24h) |
CBX-12 (acidic microenvironment) |
| Reduction-Sensitive (Disulfide) |
Intracellular high GSH reduction |
Medium–High |
High |
Fast (1–4h) |
BT1718 (DM1) |
| β-Glucuronide Linker |
β-Glucuronidase cleavage |
High |
High |
Moderate (4–12h) |
Next-gen PDC design |
| Non-Cleavable Linker |
Requires lysosomal peptide degradation |
Very High |
Low |
Slow (>24h) |
Less used for PDCs |
| Phosphatase-Sensitive |
Alkaline phosphatase cleavage |
High |
High |
Moderate |
Frontier research |
| UV/Light-Sensitive |
UV irradiation cleavage |
Very High |
Controllable |
Condition-triggered |
Photodynamic PDC |
5. PDC vs ADC vs Small Molecule Conjugate Comparison
| Parameter |
PDC |
ADC |
SMDC |
| Molecular Weight |
1–5 kDa |
~150 kDa |
0.5–2 kDa |
| Targeting Ligand |
Peptide (linear/cyclic/bicycle) |
Monoclonal antibody |
Small molecule (folate/PSMA) |
| Tissue Penetration |
⭐⭐⭐⭐ High (deep tumor penetration) |
⭐⭐ Low (penetration-limited) |
⭐⭐⭐⭐⭐ Very high |
| Immunogenicity |
Low–Very Low |
Medium–High |
Very Low |
| Production Cost |
$1,000–5,000/g |
$10,000–50,000/g |
$200–1,000/g |
| Payload Release Rate |
Fast (hours) |
Slow (days) |
Fast (1–2h) |
| DAR |
1–4 (precisely controllable) |
2–8 (distribution range) |
1–2 |
| Tumor Accumulation Time |
Fast but rapid washout |
Slow but persistent |
Fast |
| Number Approved |
3 (incl. radionuclide type) |
~15 |
~5 |
| Clinical Development Success Rate |
Lower (yet to be validated) |
✅ Well validated |
Medium |
| Tumor/Normal Tissue Ratio |
Medium (5–15:1) |
High (20–50:1) |
Low (2–5:1) |
| Oral Feasibility |
Very Low (typically injectable) |
Not orally available |
Potentially oral |
| Platform |
Company |
Core Technology |
Pipeline Count |
Differentiation Advantage |
| Bicycle |
Bicycle Therapeutics |
Phage display bicycle peptide discovery platform |
>10 |
Bicycle peptides: high affinity + high stability |
| pHLIP |
Cybrexa/MorphoSys |
pH-sensitive cell-penetrating peptide targeting |
3 |
Tumor acidic microenvironment selectivity |
| Sortilin |
Theratechnologies |
Specific receptor-mediated endocytosis |
2 |
Unique Sortilin receptor target |
| Cend-1 |
Cend Therapeutics |
iRGD tumor-penetrating peptide |
2 |
Penetrating peptide enhances EPR effect |
| RGD Peptide Platform |
Henlius/Biosion |
Integrin-targeting RGD peptides |
5+ |
Most mature targeting peptide system in China |
| PPMX Cyclic Peptide |
PPMX (Japan) |
Hypoxia-responsive cyclic peptides |
2 |
Unique tumor microenvironment response |
7. China PDC Enterprise Pipeline
| Company |
Pipeline PDC |
Phase |
Target |
Payload |
Linker Feature |
Differentiation |
| Biosion Biotech |
BGC0222 |
Phase I |
αvβ3/αvβ5 integrin |
CPT |
Cyclic RGD + enzyme-cleavable linker |
First Chinese PDC to enter clinic |
| Henlius |
HLX71 |
Preclinical |
Undisclosed |
Undisclosed |
Proprietary linker |
Oncology + inflammation dual track |
| SENO Biotechnology |
PDC Custom CDMO |
Technology platform |
Multi-target |
Multiple payloads |
Customizable linker design |
Synthesis process + GMP capability |
| NanoMicro Tech |
Multifunctional linker platform |
Technology platform |
— |
— |
Proprietary linker technology |
Multiple cleavage mechanisms available |
| Suzhou Crystal Pharma |
Peptide delivery system optimization |
Collaboration model |
Multi-target |
Multiple payloads |
Crystal form control tech |
GMP production collaboration |
| BeiGene |
Early-stage PDC pipeline |
Preclinical |
Undisclosed |
Undisclosed |
— |
Major pharma resource backing |
8. PDC Technology Future Directions
| Direction |
Technology Description |
Representative Progress |
Expected Commercialization |
| Dual-Targeting PDC |
Simultaneous targeting of two receptors for improved selectivity |
Bicycle BT7480 (Nectin-4/CD137) |
2026–2028 |
| Multimodal PDC |
Diagnostics + therapy integration (Theranostics) |
Lutathera/Pluvicto validated |
Already commercial |
| Immunostimulatory PDC |
Payload = immune agonist (STING/TLR) |
Bicycle immune PDC pipeline |
2027–2030 |
| Oral PDC |
Oral delivery of conjugated drugs |
Cyclic peptide oral delivery platforms |
2028+ |
| Dual-Payload PDC |
Same peptide carrying two different payloads |
Combination therapy PDCs |
2027+ |
| AI-Assisted PDC Design |
Machine learning optimization of linkers and targeting peptides |
Multiple AI pharma collaborations |
2025–2027 |
| BBB-Crossing PDC |
Targeted peptide conjugates penetrating the blood-brain barrier |
Transferrin receptor-targeting peptides |
2027–2030 |
9. PDC Clinical Development Key Challenges
| Challenge Dimension |
Specific Issue |
Severity |
Current Solution Strategy |
Representative Case |
| Targeting Peptide Affinity |
Linear peptides degrade easily, affinity lower than antibodies |
🔴 High |
Bicycle/cyclic peptides improve stability |
Bicycle peptide platform |
| Payload Release Kinetics |
Too fast → systemic toxicity; too slow → insufficient efficacy |
🔴 High |
Smart linker design (pH/enzyme dual-response) |
CBX-12 pH-sensitive linker |
| Tumor Retention Time |
PDC cleared rapidly, insufficient intra-tumoral accumulation |
🟡 Medium |
PEGylation/multimerization prolongs retention |
PEGylated PDCs in development |
| Non-Specific Uptake |
Non-targeted accumulation of peptides in liver/kidney |
🔴 High |
Improve targeting peptide selectivity |
Dual-targeting strategy |
| Scale-Up Synthesis |
Low yield for cyclic/bicycle peptides |
🟡 Medium |
Continuous flow + enzymatic synthesis optimization |
Bicycle GMP process |
| Regulatory Pathway |
No dedicated PDC approval guidelines yet |
🟡 Medium |
Referencing ADC + radiopharmaceutical dual pathways |
FDA/EMA discussions ongoing |
Data Sources: ClinicalTrials.gov, Bicycle Therapeutics corporate website, company annual reports, Nature Reviews Drug Discovery. PDCs represent the next-generation targeted delivery technology with significant advantages in molecular weight, penetration, and cost. However, optimization of payload release kinetics and tumor retention remain key challenges. For PDC drug synthesis process development, linker design, or GMP production services — contact SENO Biotechnology — Professional Peptide CDMO, visit senopeptide.com/platforms/ for PDC technology development support.